Your browser is no longer supported. Please, upgrade your browser.
Settings
BLUE bluebird bio, Inc. daily Stock Chart
BLUE [NASD]
bluebird bio, Inc.
Index- P/E- EPS (ttm)-8.19 Insider Own0.30% Shs Outstand57.33M Perf Week-0.78%
Market Cap7.19B Forward P/E- EPS next Y-11.04 Insider Trans-42.18% Shs Float54.45M Perf Month2.62%
Income-417.80M PEG- EPS next Q-2.80 Inst Own99.70% Short Float8.44% Perf Quarter-21.02%
Sales39.50M P/S181.92 EPS this Y25.40% Inst Trans0.70% Short Ratio6.45 Perf Half Y-30.85%
Book/sh37.55 P/B3.34 EPS next Y-2.60% ROA-26.60% Target Price200.65 Perf Year-21.74%
Cash/sh29.57 P/C4.24 EPS next 5Y- ROE-31.50% 52W Range102.21 - 236.17 Perf YTD-29.62%
Dividend- P/FCF- EPS past 5Y17.50% ROI-12.70% 52W High-46.93% Beta2.38
Dividend %- Quick Ratio13.10 Sales past 5Y153.30% Gross Margin- 52W Low22.63% ATR8.07
Employees659 Current Ratio13.10 Sales Q/Q49.40% Oper. Margin- RSI (14)49.65 Volatility6.85% 7.29%
OptionableYes Debt/Eq0.08 EPS Q/Q-58.20% Profit Margin- Rel Volume0.70 Prev Close122.78
ShortableYes LT Debt/Eq0.08 EarningsNov 07 AMC Payout- Avg Volume712.74K Price125.34
Recom2.00 SMA203.11% SMA50-5.12% SMA200-25.17% Volume500,563 Change2.09%
Nov-14-18Upgrade Bernstein Mkt Perform → Outperform
Nov-05-18Upgrade Janney Neutral → Buy
Nov-02-18Upgrade Cantor Fitzgerald Underweight → Neutral $122 → $134
Jul-12-18Initiated Gabelli & Co Buy $239
Jun-19-18Upgrade Evercore ISI In-line → Outperform
Mar-21-18Reiterated Morgan Stanley Equal-Weight $152 → $209
Mar-14-18Initiated Janney Neutral
Mar-05-18Initiated William Blair Outperform
Feb-22-18Reiterated Cantor Fitzgerald Underweight $122 → $113
Jan-25-18Downgrade Leerink Partners Outperform → Mkt Perform
Dec-21-17Initiated Oppenheimer Perform
Dec-13-17Reiterated Barclays Overweight $162 → $209
Dec-13-17Downgrade Maxim Group Buy → Hold $200
Dec-11-17Upgrade Jefferies Hold → Buy $130 → $211
Dec-11-17Reiterated Goldman Buy $186 → $309
Dec-11-17Reiterated Cantor Fitzgerald Underweight $58 → $113
Dec-05-17Initiated Canaccord Genuity Buy $202
Nov-30-17Reiterated Maxim Group Buy $170 → $200
Nov-06-17Downgrade Evercore ISI Outperform → In-line
Nov-03-17Upgrade Morgan Stanley Underweight → Equal-Weight
Nov-17-18 08:31AM  My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy Motley Fool
Nov-16-18 03:48PM  Edited Transcript of BLUE earnings conference call or presentation 2-Nov-18 12:00pm GMT Thomson Reuters StreetEvents
08:40AM  Market Trends Toward New Normal in PlayAGS, BEST, Inc. Sponsored ADR, Verrica Pharmaceuticals, Telenav, bluebird bio, and CompX International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and bluebird bio ACCESSWIRE
Nov-15-18 08:00AM  bluebird bio to Present at the Evercore ISI HealthCONx Conference Business Wire +5.40%
Nov-09-18 04:32PM  Waiting for bluebird bio to Sing at ASH Motley Fool
Nov-07-18 10:32PM  Here's Why bluebird bio Fell 21.4% in October Motley Fool
09:16AM  3 Cancer Stocks to Watch in December Motley Fool
08:24AM  3 Top Biotech Stocks to Buy in November Motley Fool
Nov-06-18 06:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Geron ACCESSWIRE
Nov-05-18 12:09PM  Janney Upgrades bluebird bio Ahead Of Sickle Cell Presentation Benzinga
Nov-02-18 10:17AM  bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat Zacks
Nov-01-18 06:20PM  Bluebird Bio (BLUE) Reports Q3 Loss, Tops Revenue Estimates Zacks +13.47%
05:18PM  Here's Why bluebird bio Jumped 13.5% Today Motley Fool
05:14PM  Bluebird: 3Q Earnings Snapshot Associated Press
04:00PM  bluebird bio Reports Third Quarter 2018 Financial Results and Highlights Operational Progress Business Wire
09:00AM  bluebird bio to Present New Data from Early- and Late-Stage Pipeline of Investigational Gene and Cell Therapies at the American Society of Hematology Annual Meeting Business Wire
Oct-31-18 08:00AM  Today's Research Reports on Trending Tickers: bluebird bio and Sarepta Therapeutics ACCESSWIRE
Oct-26-18 08:34AM  Here's Why I'm Not Selling My Celgene Shares Motley Fool
Oct-11-18 01:41PM  Here's Why bluebird bio Dropped 13.3% in September Motley Fool
Oct-05-18 05:00AM  bluebird bio Announces European Medicines Agencys Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia Business Wire
Oct-01-18 08:00AM  bluebird bio to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology Business Wire
Sep-28-18 08:30AM  Today's Research Reports on Trending Tickers: bluebird bio and Regeneron Pharmaceuticals ACCESSWIRE
Sep-25-18 03:59PM  Bullish Divergences on Bluebird Bio Tell Me This Stock Can Sing TheStreet.com
Sep-14-18 10:15AM  Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory Motley Fool
Sep-12-18 06:00PM  Bluebird Bio Stock May Have Upside of at Least 60 Percent InvestorPlace
Sep-07-18 08:00AM  Today's Research Reports on Trending Tickers: bluebird bio and PTC Therapeutics ACCESSWIRE
Sep-05-18 08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga
06:11AM  bluebird bio Presents Updated Data from Phase 2/3 Starbeam Study of Investigational Lenti-D Gene Therapy for CALD and Initial Data from Observational Study ALD-103 of Allogeneic Hematopoietic Stem Cell Transplant in CALD at 2018 SSIEM Business Wire
Aug-30-18 06:06PM  Software and Biotech Are Eating the World Zacks
Aug-29-18 08:00AM  bluebird bio to Present at Investor Conferences in September Business Wire
Aug-28-18 08:00AM  Today's Research Reports on Trending Tickers: Exelixis and bluebird bio ACCESSWIRE
Aug-27-18 12:14PM  Play The Future of Gene Therapy With These 5 Biotech Stocks InvestorPlace
Aug-23-18 05:47PM  East Bay biotech's different approach to cancer leads to $80 million IPO American City Business Journals
03:48PM  Lake Union biotech leases signal resurgence of life science market American City Business Journals
06:30AM  bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies Business Wire
Aug-16-18 07:00AM  Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musks Tail Market Exclusive
Aug-15-18 06:20AM  Express Scripts staking out million-dollar gene therapies Reuters
Aug-09-18 10:25PM  Carl Icahn Fires Shots at Express Scripts Motley Fool
Aug-08-18 07:52AM  Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges Zacks
Aug-07-18 11:30AM  Why this company's Durham outpost may benefit from $100M investment American City Business Journals
08:00AM  Today's Research Reports on Trending Tickers: Spark Therapeutics and bluebird bio ACCESSWIRE
Aug-06-18 04:15PM  Can These Biotech Companies Catch Novartis, Gilead In CAR-T? Investor's Business Daily
02:47PM  bluebird bio Prepares Its "Transition to a Commercial Company" Motley Fool
12:06PM  Bluebird Bio Stock Is for Long-Term Investors Only InvestorPlace
11:59AM  Small Biotechs See Big Gains as Bluebird, Intercept Fly Barrons.com
11:44AM  Why Is Bluebird Bio (BLUE) Stock Gaining Today? Zacks
11:02AM  Regeneron To Make $100M bluebird bio Investment In Cancer Research Collaboration Benzinga
09:40AM  Stocks Slip As Intel Downgrade Crimps Dow, Qualcomm Upgraded Investor's Business Daily
09:39AM  Bluebird Bio stock lifts on Regeneron collaboration, $100 mln investment MarketWatch
06:30AM  Regeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer PR Newswire
06:30AM  bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer Business Wire
Aug-03-18 04:05PM  bluebird bio to Present Updated Data for Lenti-D Gene Therapy for Cerebral Adrenoleukodystrophy at SSIEM 2018 Symposium Business Wire
12:54PM  bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss Zacks
07:30AM  bluebird bio to Present at the 2018 Wedbush PacGrow Healthcare Conference Business Wire
Aug-02-18 10:45AM  Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates Zacks
09:45AM  Bluebird: 2Q Earnings Snapshot Associated Press
06:30AM  bluebird bio Reports Second Quarter 2018 Financial Results and Highlights Operational Progress Business Wire
Jul-27-18 04:05PM  bluebird bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jul-26-18 04:30PM  bluebird bios LentiGlobin Gene Therapy Granted Accelerated Assessment by European Medicines Agency for the Treatment of Transfusion-Dependent -Thalassemia Business Wire
Jul-25-18 12:54PM  Trump's Trade War Against U.S. Allies Is a Direct Hit to Key Industries TheStreet.com +5.41%
07:00AM  Did This Top Biotech Stock Just Go on Sale? Motley Fool
Jul-24-18 07:32PM  bluebird bio Announces Pricing of Public Offering of Common Stock Business Wire -7.67%
03:38PM  Here's Why bluebird bio, Inc. Is Down Today Motley Fool
08:53AM  Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering Benzinga
Jul-23-18 04:01PM  bluebird bio Announces Proposed Public Offering of Common Stock Business Wire
Jul-08-18 03:15PM  Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far Motley Fool
Jul-06-18 08:20AM  Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio ACCESSWIRE
Jun-30-18 07:16AM  Celgene Investors Breathe a Sigh of Relief After Acceleron's Success Motley Fool
Jun-28-18 07:40AM  Analysis: Positioning to Benefit within EMCOR Group, Ring Energy, A. O. Smith, bluebird bio, Ligand Pharmaceuticals, and Synovus Financial Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-27-18 06:11PM  Why Sangamo Therapeutics and bluebird bio Slipped Lower Today Motley Fool
Jun-25-18 08:05AM  Today's Research Reports on Stocks to Watch: bluebird and Ampio Pharmaceuticals ACCESSWIRE -5.15%
Jun-23-18 10:21AM  Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives Benzinga
Jun-21-18 08:25AM  Today's Research Reports on Trending Tickers: bluebird bio and Exelixis ACCESSWIRE
Jun-19-18 07:30AM  Blog Exposure - bluebird bio Announces Encouraging New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin(TM) Gene Therapy in Patients with Transfusion-Dependent -Thalassemia ACCESSWIRE
07:00AM  Free Technical Research on BioPharmX and Three More Biotech Equities bio ACCESSWIRE
Jun-15-18 08:20AM  Today's Research Reports on Trending Tickers: Puma Biotechnology and bluebird bio ACCESSWIRE -7.06%
06:00AM  bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent -Thalassemia at Annual Congress of the European Hematology Association Business Wire
06:00AM  Bluebird Bio Gene Therapies Show Promise Against Deadly Anemias Forbes
06:00AM  bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association Business Wire
Jun-13-18 02:55PM  Hematology Conference Could Spur Some of Biotech's Outperformers Bloomberg
Jun-05-18 08:20AM  Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio ACCESSWIRE
08:00AM  bluebird bio Announces Investor Events in June Business Wire
Jun-04-18 05:09PM  Bluebird Bio's Multiple Myeloma Data Reinforces Canaccord Genuity's Bullish Thesis Benzinga
04:16PM  Could Celgene Shake Up the CAR-T Market? Motley Fool
09:38AM  Bluebird Bio shares lift 9% on CAR-T cancer therapy results MarketWatch
Jun-03-18 02:10PM  #ASCO18: A Weekend of Surprises Motley Fool
Jun-01-18 09:22PM  Is bluebird bio Inc (NASDAQ:BLUE) Worth $182.8 Based On Intrinsic Value? Simply Wall St.
06:13PM  Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet Forbes
05:57PM  Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Business Wire
May-30-18 07:40AM  Something Borrowed, Something Blue, Volume 2: It's Been a Roller-Coaster Ride for BLUE Shareholders Motley Fool
07:02AM  Something Old, Something New, Something Borrowed, Volume 2: A Particularly Motley Podcast Motley Fool
May-24-18 06:31AM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio Motley Fool
May-23-18 08:00AM  FDA Grants Breakthrough Therapy Designation to Lenti-D for the Treatment of Cerebral Adrenoleukodystrophy Business Wire
May-17-18 12:27PM  Is bluebird bio Incs (NASDAQ:BLUE) Liquidity Good Enough? Simply Wall St. +6.11%
09:00AM  bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent -Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association Business Wire
May-16-18 05:00PM  bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Business Wire
May-15-18 08:30AM  Investor Expectations to Drive Momentum within Aerohive Networks, M/I Homes, bluebird bio, Penske Automotive Group, Sanmina, and Genesco Discovering Underlying Factors of Influence GlobeNewswire
May-14-18 08:00AM  Today's Research Reports on Trending Tickers: Omeros and bluebird bio ACCESSWIRE
03:49AM  Medigene in for up to $1.5 bln under broader pact with Bluebird Bio Reuters
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy; and Gritstone Oncology, Inc. to research, develop, and commercialize products for the treatment of cancer using cell therapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walsh Jeffrey T.Chief FinancialNov 09Option Exercise24.471,50036,70536,995Nov 14 04:10 PM
Walsh Jeffrey T.Chief FinancialNov 09Sale130.591,500195,89135,495Nov 14 04:10 PM
Gregory Philip DChief Scientific OfficerNov 05Option Exercise64.021,30083,22632,671Nov 07 04:14 PM
Gregory Philip DChief Scientific OfficerNov 05Sale137.381,800247,27730,871Nov 07 04:14 PM
Davidson DavidChief Medical OfficerNov 02Option Exercise5.505,00027,50229,905Nov 06 04:15 PM
Davidson DavidChief Medical OfficerNov 02Sale133.645,000668,21624,905Nov 06 04:15 PM
Walsh Jeffrey T.Chief FinancialOct 10Option Exercise24.471,50036,70536,995Oct 12 04:53 PM
Walsh Jeffrey T.Chief FinancialOct 10Sale135.231,500202,83935,495Oct 12 04:53 PM
Gregory Philip DChief Scientific OfficerOct 05Option Exercise64.021,30083,22633,171Oct 10 04:17 PM
Gregory Philip DChief Scientific OfficerOct 05Sale140.561,800253,00031,371Oct 10 04:17 PM
Davidson DavidChief Medical OfficerOct 02Option Exercise5.505,00027,50229,905Oct 04 04:21 PM
Davidson DavidChief Medical OfficerOct 02Sale139.325,000696,58824,905Oct 04 04:21 PM
Walsh Jeffrey T.Chief FinancialSep 10Option Exercise24.471,50036,70536,995Sep 12 04:12 PM
Walsh Jeffrey T.Chief FinancialSep 10Sale150.161,500225,24335,495Sep 12 04:12 PM
Mandell JamesDirectorSep 10Sale150.771,000150,7711,000Sep 12 04:07 PM
Gregory Philip DChief Scientific OfficerSep 05Option Exercise64.021,30083,22633,671Sep 07 04:32 PM
Gregory Philip DChief Scientific OfficerSep 05Sale163.021,800293,44131,871Sep 07 04:32 PM
Davidson DavidChief Medical OfficerSep 04Option Exercise5.507,00038,50331,905Sep 06 04:12 PM
Davidson DavidChief Medical OfficerSep 04Sale166.647,0001,166,49324,905Sep 06 04:12 PM
Walsh Jeffrey T.Chief FinancialAug 30Option Exercise10.8820,000217,68955,495Sep 04 05:03 PM
Walsh Jeffrey T.Chief FinancialAug 30Sale175.4020,0003,507,94835,495Sep 04 05:03 PM
FINGER ALISON CECILYChief Commercial OfficerAug 20Sale158.0725940,94015,667Aug 22 06:32 AM
Walsh Jeffrey T.Chief FinancialAug 10Option Exercise5.501,5008,25136,995Aug 14 04:47 PM
Walsh Jeffrey T.Chief FinancialAug 10Sale156.931,500235,38935,495Aug 14 04:47 PM
Cole JasonChief Legal OfficerAug 08Option Exercise22.534,43899,98821,610Aug 10 06:48 AM
Gregory Philip DChief Scientific OfficerAug 06Option Exercise64.021,30083,22634,171Aug 08 04:06 PM
Gregory Philip DChief Scientific OfficerAug 06Sale156.611,800281,88932,371Aug 08 04:06 PM
Davidson DavidChief Medical OfficerAug 02Option Exercise5.507,00038,50331,905Aug 06 04:08 PM
Walsh Jeffrey T.Chief FinancialAug 02Option Exercise5.5021,500118,25956,995Aug 06 04:10 PM
Walsh Jeffrey T.Chief FinancialAug 02Sale152.0221,5003,268,49335,495Aug 06 04:10 PM
Davidson DavidChief Medical OfficerAug 02Sale150.377,0001,052,58524,905Aug 06 04:08 PM
Davidson DavidChief Medical OfficerJul 11Option Exercise5.503,00016,50127,905Jul 13 04:31 PM
Davidson DavidChief Medical OfficerJul 11Sale180.153,000540,44324,905Jul 13 04:31 PM
Cole JasonChief Legal OfficerJul 09Sale170.255,126872,71517,172Jul 11 04:10 PM
Davidson DavidChief Medical OfficerJul 02Option Exercise5.5010,00055,00434,905Jul 03 04:10 PM
Davidson DavidChief Medical OfficerJul 02Sale153.9610,0001,539,60424,905Jul 03 04:10 PM
Gregory Philip DChief Scientific OfficerJun 18Sale178.413,901695,97825,371Jun 20 04:29 PM
Vachon MarkDirectorJun 14Sale189.991,000189,9920Jun 18 04:43 PM
HIGH SUSANNA GATTIChief Operating OfficerJun 04Option Exercise68.653,500240,27521,000Jun 06 04:36 PM
Davidson DavidChief Medical OfficerJun 04Option Exercise24.4713,000318,11037,905Jun 06 04:39 PM
Vachon MarkDirectorJun 04Option Exercise42.076,000252,4207,000Jun 06 04:42 PM
Davidson DavidChief Medical OfficerJun 04Sale187.8413,0002,441,96524,905Jun 06 04:39 PM
Vachon MarkDirectorJun 04Sale188.226,0001,129,3011,000Jun 06 04:42 PM
HIGH SUSANNA GATTIChief Operating OfficerJun 04Sale199.113,500696,89217,500Jun 06 04:36 PM
Cole JasonChief Legal OfficerMay 04Sale170.893,750640,84922,298May 08 04:18 PM
Davidson DavidChief Medical OfficerMay 02Option Exercise24.4713,000318,11037,905May 04 04:39 PM
Davidson DavidChief Medical OfficerMay 02Sale177.5213,0002,307,69624,905May 04 04:39 PM
Davidson DavidChief Medical OfficerApr 12Option Exercise24.473,00073,41027,905Apr 16 04:48 PM
Davidson DavidChief Medical OfficerApr 12Sale180.173,000540,50824,905Apr 16 04:48 PM
Davidson DavidChief Medical OfficerApr 02Option Exercise24.4722,000538,34046,905Apr 04 04:47 PM
Gregory Philip DChief Scientific OfficerApr 02Option Exercise50.511,25063,13831,522Apr 04 04:50 PM
Gregory Philip DChief Scientific OfficerApr 02Sale168.712,250379,60829,272Apr 04 04:50 PM
Davidson DavidChief Medical OfficerApr 02Sale167.5222,0003,685,38724,905Apr 04 04:47 PM
Vachon MarkDirectorMar 15Option Exercise30.476,000182,8207,000Mar 19 04:06 PM
Vachon MarkDirectorMar 15Sale214.386,0001,286,2501,000Mar 19 04:06 PM
Davidson DavidChief Medical OfficerMar 02Option Exercise5.504,00022,00228,905Mar 06 04:29 PM
Davidson DavidChief Medical OfficerMar 02Sale201.194,000804,75124,905Mar 06 04:29 PM
Gregory Philip DChief Scientific OfficerMar 01Option Exercise50.511,25063,13832,522Mar 05 05:14 PM
Gregory Philip DChief Scientific OfficerMar 01Sale200.002,250449,99530,272Mar 05 05:14 PM
HIGH SUSANNA GATTIChief Operating OfficerFeb 28Option Exercise68.651,04471,67118,544Mar 02 04:01 PM
HIGH SUSANNA GATTIChief Operating OfficerFeb 28Sale202.671,044211,59217,500Mar 02 04:01 PM
Davidson DavidChief Medical OfficerFeb 02Option Exercise5.504,00022,00228,905Feb 05 04:01 PM
Davidson DavidChief Medical OfficerFeb 02Sale202.364,000809,44124,905Feb 05 04:01 PM
Gregory Philip DChief Scientific OfficerFeb 01Option Exercise50.511,25063,13833,522Feb 05 04:02 PM
Gregory Philip DChief Scientific OfficerFeb 01Sale204.902,250461,02031,272Feb 05 04:02 PM
Cole JasonChief Legal OfficerJan 30Option Exercise22.5325,000563,25044,798Feb 01 04:30 PM
HIGH SUSANNA GATTIChief Operating OfficerJan 30Option Exercise68.6514,7941,015,60828,512Feb 01 04:31 PM
HIGH SUSANNA GATTIChief Operating OfficerJan 30Sale195.9117,2623,381,79211,250Feb 01 04:31 PM
Cole JasonChief Legal OfficerJan 30Sale195.9125,0004,897,74319,798Feb 01 04:30 PM
Davidson DavidChief Medical OfficerJan 08Option Exercise5.501,2006,60014,855Jan 09 04:05 PM
Davidson DavidChief Medical OfficerJan 08Sale174.071,200208,88313,655Jan 09 04:05 PM
Gregory Philip DChief Scientific OfficerJan 05Sale173.381,712296,82023,772Jan 09 04:06 PM
Leschly NickPresident and CEOJan 05Sale173.385,435942,298170,297Jan 09 04:06 PM
Walsh Jeffrey T.Chief FinancialJan 05Sale173.383,060530,53024,245Jan 09 04:07 PM
Cole JasonChief Legal OfficerJan 05Sale173.381,129195,74119,798Jan 09 04:05 PM
Davidson DavidChief Medical OfficerJan 05Sale173.382,322402,57913,655Jan 09 04:05 PM
Davidson DavidChief Medical OfficerJan 03Option Exercise5.506,00033,00221,977Jan 05 04:10 PM
Gregory Philip DChief Scientific OfficerJan 03Option Exercise50.511,25063,13827,734Jan 05 04:11 PM
Gregory Philip DChief Scientific OfficerJan 03Sale180.692,250406,55025,484Jan 05 04:11 PM
Davidson DavidChief Medical OfficerJan 03Sale180.306,0001,081,78115,977Jan 05 04:10 PM
Leschly NickPresident and CEODec 13Option Exercise5.5037,873208,317293,232Dec 15 04:09 PM
Leschly NickPresident and CEODec 13Sale184.08117,50021,629,119175,732Dec 15 04:09 PM
Vachon MarkDirectorDec 11Option Exercise30.476,000182,8208,000Dec 13 04:10 PM
Walsh Jeffrey T.Chief FinancialDec 11Option Exercise24.479,900242,25337,205Dec 13 04:09 PM
Walsh Jeffrey T.Chief FinancialDec 11Sale216.549,9002,143,78527,305Dec 13 04:09 PM
Vachon MarkDirectorDec 11Sale216.647,0001,516,4651,000Dec 13 04:10 PM
Gregory Philip DChief Scientific OfficerDec 01Option Exercise50.511,25063,13828,734Dec 05 04:08 PM
Davidson DavidChief Medical OfficerDec 01Option Exercise5.504,00022,00219,977Dec 05 04:08 PM
HIGH SUSANNA GATTIChief Operating OfficerDec 01Sale172.151,282220,69613,718Dec 05 04:09 PM
Davidson DavidChief Medical OfficerDec 01Sale172.424,000689,67915,977Dec 05 04:08 PM
Gregory Philip DChief Scientific OfficerDec 01Sale172.542,250388,21126,484Dec 05 04:08 PM